- Health Topics
- The Science
- Grants and Training
- News and Events
- About NHLBI
Understanding COVID-19
What is COVID-19?
Learn more about COVID-19, also known as Coronavirus 2019.
Medical Animation Copyright © 2020 Nucleus Medical Media, All rights reserved.
How does COVID-19 affect your body?
Learn more about COVID-19, and how the virus can affect your body.
Medical Animation Copyright © 2020 Nucleus Medical Media, All rights reserved.
How does COVID-19 affect your lungs?
Medical Animation Copyright © 2020 Nucleus Medical Media, All rights reserved.
How does COVID-19 affect your heart?
Medical Animation Copyright © 2020 Nucleus Medical Media, All rights reserved.
How does COVID-19 affect your blood?
Medical Animation Copyright © 2020 Nucleus Medical Media, All rights reserved.
NHLBI's Research Strategy
Director's Blog
November 17, 2020
Can Autoimmune Antibodies Explain Blood Clots in COVID-19?
NIH Director Dr. Francis Collins
Can Autoimmune Antibodies Explain Blood Clots in COVID-19?
NIH Director Dr. Francis Collins
For people with severe COVID-19, one of the most troubling complications is abnormal blood clotting that puts them at risk of having a debilitating stroke or heart attack. A new study funded by the National Heart, Lung, and Blood Institute suggests that SARS-CoV-2, the coronavirus that causes COVID-19, doesn’t act alone in causing blood clots. The virus seems to unleash mysterious antibodies that mistakenly attack the body’s own cells to cause clots.
Related News
Full-dose blood thinners decreased need for life support and improved outcome in hospitalized COVID-19 patients
In large clinical trials conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ support—such as the need for mechanical ventilation. A trend in possible reduction of mortality was also observed and is being further studied. With...
At-home monitoring devices, tools play leading role in patient care during pandemic
When you think of the San Francisco Bay Area, those young, tech-savvy college graduates who work for some of the world’s largest software companies there may first come to mind. But this bustling metropolitan area is also home to nearly 1.5 million people age 65 and older . So when the city went into its first lockdown in March to try to halt the...
NIH ACTIV trial of blood thinners pauses enrollment of critically ill COVID-19 patients
Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients. Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, therapeutic anticoagulation drugs did not reduce the need for organ support....
Could lessons from heart disease battle help American Indian community fight COVID-19?
When the results from a landmark heart health study of American Indians were published in 1999, they shattered the health care community’s erroneous assumption that this population rarely got heart disease—that somehow they were naturally protected from it. Indeed, the study highlighted the exceedingly high rate of heart disease and its risk...
Arterial wall cells offer insight into coronavirus’ rampage from head to toe
Peter Libby, M.D., never imagined nearly 40 years ago that his research would contribute to the current understanding of how the novel coronavirus targets and ravages the blood vessels in people with COVID-19. In the 1980s, Libby, then an assistant professor of medicine at Tufts University School of Medicine, was the first to discover that arterial...
Tracking a Mysterious Condition in Children
NIH study follows rare immune response to COVID-19 On a late October morning in southern Wyoming, 12-year-old Madilyn Dayton woke up feeling sick. The normally energetic child assumed she was coming down with a common cold, but in short order her symptoms got worse. “I had a really bad headache and just body aches all over,” said Madilyn, who goes...
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was...
NIH funds community engagement research efforts in areas hardest hit by COVID-19
The National Institutes of Health today announced a $12 million award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic. The award to RTI International, a non-profit research institution, will support teams in 11 states established as part of the NIH Community...
NIH ACTIV initiative launches adaptive clinical trials of blood clotting treatments for COVID-19
The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100...
COVID-19 Posing Grim Challenge for Sickle Cell Disease Patients
The coronavirus pandemic has caused tragedy and turmoil for millions of people around the world, but it has been particularly unkind to one group whose health journey is often overlooked: Those with sickle cell disease. A growing number of studies now suggest that people with this painful genetic blood disorder who also are infected with SARS-CoV-2...
